MI
Therapeutic Areas
Otsuka Holdings Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Abilify (aripiprazole) | Schizophrenia, Bipolar Disorder | Commercial |
| Rexulti (brexpiprazole) | Major Depressive Disorder, Schizophrenia | Commercial |
| Abilify Maintena | Schizophrenia, Bipolar I Disorder | Commercial |
| OPC-64005 | Alzheimer's Disease Psychosis | Phase 3 |
| Centanafadine | ADHD | Phase 3 |
| OPC-34712 | Major Depressive Disorder | Phase 2 |
| Nuedexta (AVP-923) | Pseudobulbar Affect | Commercial |
| Jynarque/Jinarc (tolvaptan) | ADPKD | Commercial |
Leadership Team at Otsuka Holdings
TI
Taro Iwamoto
Representative Director, Executive Vice President and CFO
IO
Ichiro Otsuka
Chairman of the Board
WC
William Carson
Chief Medical Officer, Otsuka Pharmaceutical Development & Commercialization
KN
Kabir Nath
CEO, Otsuka America Pharmaceutical